Table 4.
Reference | Year | n | Treatment regimen | ORR (%) | p | Median PFS/TTP (mo) | p |
Louvet | 2005 | 156 | Gemcitabine | 17.3 | 0.04 | 3.7 | 0.04 |
157 | Gemcitabine (FDR) + Oxaliplatin | 26.8 | 5.8 | ||||
Poplin | 2006 | 279 | Gemcitabine (standard) | 5 | -- | na | na |
277 | Gemcitabine (FDR) | 10 | -- | ||||
276 | Gemcitabine (FDR) + Oxaliplatin | 9 | -- | ||||
Heinemann | 2006 | 95 | Gemcitabine | 8.2 | -- | 3.1 | 0.053 |
95 | Gemcitabine + Cisplatin | 10.2 | 5.3 | ||||
Colucci | 2002 | 54 | Gemcitabine | 9.2 | 0.02 | 2.0 | 0.048 |
53 | Gemcitabine + Cisplatin | 26.4 | 5.0 | ||||
Viret | 2004 | 41 | Gemcitabine | 5 | -- | 2.5 | ns |
42 | Gemcitabine + Cisplatin | 7 | 2.2 |
ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression; FDR = fixed dose rate; na = data not available; ns = not significant;